Ranitidine bismuth citrate-based triple therapy for seven days, with or without further anti-secretory therapy, is highly effective in patients with duodenal ulcer and Helicobacter pylori infection.
Objective: To compare the efficacy of two protocols for the eradication of Helicobacter pylori infection and the healing of active duodenal ulcer: (i) ranitidine bismuth citrate (RBC) plus two antibiotics for 7 days, and (ii) the same triple therapy followed by 3 weeks of anti-secretory drug treatme...
| Publicado en: | European Journal of Gastroenterology & Hepatology Vol. 13; no. 5; pp. 547 - 551 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
2001 May
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107042451&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 107042451 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0954691X 8CE jtl: European Journal of Gastroenterology & Hepatology issn: 0954691X maglogo: N pubinfo: dt: 2001 May vid: 13 iid: 5 pid: 5086 pub: Lippincott Williams & Wilkins place: Baltimore, Maryland artinfo: ui: 107042451 107042451 NLM11396535 2001071302 10.1097/00042737-200105000-00014 NLM11396535 107042451 ppf: 547 ppct: 4 formats: tig: atl: Ranitidine bismuth citrate-based triple therapy for seven days, with or without further anti-secretory therapy, is highly effective in patients with duodenal ulcer and Helicobacter pylori infection. aug: au: Marchi S Costa F Bellini M Belcari C Mumolo MG Tornar A Spisni R Torelli E Maltinti G Marchi, S Costa, F Bellini, M Belcari, C Mumolo, M G Tornar, A Spisni, R Torelli, E Maltinti, G affil: Department of Internal Medicine, University of Pisa, Italy sug: subj: Helicobacter Infections Drug Therapy Ranitidine Therapeutic Use Duodenal Ulcer Drug Therapy Antibiotics Therapeutic Use Drug Therapy, Combination Treatment Outcomes Clinical Trials Data Analysis Software Fisher's Exact Test Confidence Intervals Adult Middle Age Female Male Human Adult: 19-44 years Middle Aged: 45-64 years Female Male ab: Objective: To compare the efficacy of two protocols for the eradication of Helicobacter pylori infection and the healing of active duodenal ulcer: (i) ranitidine bismuth citrate (RBC) plus two antibiotics for 7 days, and (ii) the same triple therapy followed by 3 weeks of anti-secretory drug treatment.Methods: The study comprised 102 patients with active duodenal ulcer and H. pylori infection; the patients were randomized to open treatment with either RBC 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 7 days, or the same treatment followed by 3 weeks of RBC 400 mg b.d. alone. Ulcer healing was confirmed by endoscopy. H. pylori eradication was assessed by endoscopy, rapid urease test and histology.Results: The ulcer healed in 48/50 patients on RBC-based triple therapy alone (96.0%) and in 51/52 patients on triple therapy plus further anti-secretory treatment (98.1%). On an intention-to-treat basis, H. pylori had been successfully eradicated in 42/50 patients on triple therapy (84.0%) and in 44/52 patients on triple therapy plus anti-secretory treatment (84.6%), while by per protocol analysis the H. pylori eradication rates were 91.3% (42/46) and 89.8% (44/49), respectively.Conclusions: One-week triple therapy with RBC, amoxycillin and clarithromycin is highly effective in eradicating H. pylori and healing duodenal ulcers, even if not followed by anti-secretory drug treatment. pubtype: Academic Journal doctype: clinical trial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|